Programmed cell death protein blockade with pembrolizumab for classical
Hodgkin lymphoma after autologous stem cell transplantation in an
adolescent patient
- Irtiza Sheikh
, - David McCall
, - Cesar Nunez,
- Michael Roth
, - Branko Cuglievan
Irtiza Sheikh
![](https://d197for5662m48.cloudfront.net/assets/icons/omniauth/orcid-ca37582cd91a671ed5cec57770e0e96c01b4b79b8b5b75d8598fc1ddac18c974.svg)
MD Anderson Cancer Center
Corresponding Author:irtizasheikh@gmail.com
Author ProfileMichael Roth
![](https://d197for5662m48.cloudfront.net/assets/icons/omniauth/orcid-ca37582cd91a671ed5cec57770e0e96c01b4b79b8b5b75d8598fc1ddac18c974.svg)
University of Texas MD Anderson Cancer Center Children's Cancer Hospital
Author ProfileBranko Cuglievan
University of Texas MD Anderson Cancer Center
Author Profile30 Aug 2021Submitted to Pediatric Blood & Cancer 30 Aug 2021Submission Checks Completed
30 Aug 2021Assigned to Editor
31 Aug 2021Reviewer(s) Assigned
03 Sep 2021Review(s) Completed, Editorial Evaluation Pending
05 Sep 2021Editorial Decision: Revise Minor
17 Sep 20211st Revision Received
17 Sep 2021Submission Checks Completed
17 Sep 2021Assigned to Editor
17 Sep 2021Review(s) Completed, Editorial Evaluation Pending
17 Sep 2021Editorial Decision: Accept